Campbell & CO Investment Adviser LLC Takes $7.89 Million Position in Sanofi $SNY

Key Points

• Campbell & CO Investment Adviser LLC purchased 142,198 shares of Sanofi, valued at approximately $7.9 million, making it the fund's 5th largest position.
• Sanofi's recent earnings report showed a miss in EPS at $0.90 compared to an estimated $0.96, but revenue exceeded expectations at $11.34 billion.
• Several analysts have upgraded Sanofi's rating, with an average consensus rating of Buy and a target price of $62.00.

Campbell & CO Investment Adviser LLC bought a new stake in Sanofi (NASDAQ:SNY - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 142,198 shares of the company's stock, valued at approximately $7,886,000. Sanofi makes up approximately 0.6% of Campbell & CO Investment Adviser LLC's investment portfolio, making the stock its 5th largest holding.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cardinal Capital Management boosted its holdings in shares of Sanofi by 0.3% in the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after buying an additional 199 shares during the last quarter. Gradient Investments LLC lifted its holdings in Sanofi by 2.1% during the 1st quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock valued at $542,000 after purchasing an additional 200 shares during the last quarter. Perigon Wealth Management LLC lifted its holdings in Sanofi by 3.1% during the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after purchasing an additional 201 shares during the last quarter. Capital Analysts LLC lifted its holdings in Sanofi by 14.0% during the 1st quarter. Capital Analysts LLC now owns 1,664 shares of the company's stock valued at $92,000 after purchasing an additional 204 shares during the last quarter. Finally, Beacon Financial Group lifted its holdings in Sanofi by 1.6% during the 1st quarter. Beacon Financial Group now owns 14,398 shares of the company's stock valued at $799,000 after purchasing an additional 222 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Price Performance

Shares of SNY stock traded down $0.19 on Wednesday, reaching $50.11. The company had a trading volume of 2,044,486 shares, compared to its average volume of 2,698,749. The stock has a market capitalization of $123.05 billion, a PE ratio of 12.24, a price-to-earnings-growth ratio of 1.20 and a beta of 0.48. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a one year low of $44.73 and a one year high of $60.12. The business's 50-day moving average is $48.68 and its 200 day moving average is $51.67.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm's revenue was down 7.0% compared to the same quarter last year. During the same period last year, the company posted $1.73 EPS. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Barclays reissued an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Sanofi in a report on Tuesday, August 5th. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Finally, Morgan Stanley set a $56.00 price target on Sanofi in a research note on Monday, June 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Sanofi has an average rating of "Buy" and an average target price of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.